Altered HLA class i and HLA-G expression is associated with IL-10 expression in patients with cervical cancer

Pathobiology

Volumn 79, Issue 2, 2012, Pages 72-83

  Rodríguez, Josefa Antonia ^a   Galeano, Liliana ^a   Palacios, Diana María ^b,c   Gómez, Constanza ^a   Serrano, Martha Lucía ^a   Bravo, María Mercedes ^a   Combita, Alba Lucía ^a,c,d  

^a Instituto Nacional de Cancerología   (Colombia)

^b HOSPITAL UNIVERSITARIO FUNDACIÓN SANTA FE DE BOGOTÁ   (Colombia)

^c UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^d NONE   (Colombia)

Author keywords

Cervical cancer; Histocompatibility antigen class I; HLA G; Interleukin 10

Indexed keywords

HLA ANTIGEN CLASS 1; HLA G ANTIGEN; INTERLEUKIN 10;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER SURVIVAL; DOWN REGULATION; FEMALE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU;

HUMAN PAPILLOMAVIRUS; PAPILLOMAVIRIDAE;

EID: 84855173401     PISSN: 10152008     EISSN: 14230291     Source Type: Journal    
DOI: 10.1159/000334089     Document Type: Article

References (67)

1. Frazer IH: The role of the immune system in anogenital human papillomavirus. Australas J Dermatol 1998; 39(suppl 1):S5-S7. (Pubitemid 28539074)
2. Melbye M, Palefsky J, Gonzales J, Ryder LP, Nielsen H, Bergmann O, Pindborg J, Biggar RJ: Immune status as a determinant of human papillomavirus detection and its association with anal epithelial abnormalities. Int J Cancer 1990; 46: 203-206. (Pubitemid 20252077)
3. Palefsky J: Human papillomavirus-associated malignancies in HIV-positive men and women. Curr Opin Oncol 1995; 7: 437-441.
4. Rezza G, Giuliani M, Serraino D, Branca M, Benedetto A, Garbuglia A, Ippolito G, Franceschi S: Risk factors for cervical presence of human papillomavirus DNA among women at risk for HIV infection. DIANAIDS Collaborative Study Group. Epidemiol Infect 1998; 121: 173-177. (Pubitemid 28423343)
5. Garcia-Lora A, Algarra I, Garrido F: MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol 2003; 195: 346-355. (Pubitemid 36529863)
6. Garrido F, Algarra I: MHC antigens and tumor escape from immune surveillance. Adv Cancer Res 2001; 83: 117-158. (Pubitemid 32959264)
7. Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern PL: Natural history of HLA expression during tumour development. Immunol Today 1993; 14: 491-499. (Pubitemid 23301000)
8. Garrido F, Cabrera T, Lopez-Nevot MA, Ruiz-Cabello F: HLA class I antigens in human tumors. Adv Cancer Res 1995; 67: 155-195.
9. Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M, Stern PL: Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1997; 18: 89-95. (Pubitemid 27107103)
10. Breitburd F, Ramoz N, Salmon J, Orth G: HLA control in the progression of human papillomavirus infections. Semin Cancer Biol 1996; 7: 359-371. (Pubitemid 27380015)
11. Chil A, Sikorski M, Bobek M, Jakiel G, Marcinkiewicz J: Alterations in the expression of selected MHC antigens in premalignant lesions and squamous carcinomas of the uterine cervix. Acta Obstet Gynecol Scand 2003; 82: 1146-1152. (Pubitemid 37449384)
12. Hilders CG, Munoz IM, Nooyen Y, Fleuren GJ: Altered HLA expression by metastatic cervical carcinoma cells as a factor in impaired immune surveillance. Gynecol Oncol 1995; 57: 366-375.
13. Vermeulen CF, Jordanova ES, Zomerdijk-Nooijen YA, ter Haar NT, Peters AA, Fleuren GJ: Frequent HLA class I loss is an early event in cervical carcinogenesis. Hum Immunol 2005; 66: 1167-1173.
14. Koopman LA, Corver WE, van der Slik AR, Giphart MJ, Fleuren GJ: Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J Exp Med 2000; 191: 961-976.
15. Mazurenko NN, Bliev AI, Bidzhieva BA, Peskov DI, Snigur NV, Savinova EB, Kiselev FL: Loss of heterozygosity at chromosome 6 as a marker of early genetic alterations in cervical intraepithelial neoplasias and microinvasive carcinomas (in Russian). Mol Biol (Mosk) 2006; 40: 436-447.
16. Carosella ED, Favier B, Rouas-Freiss N, Moreau P, LeMaoult J: Beyond the increasing complexity of the immunomodulatory HLA-G molecule. Blood 2008; 111: 4862-4870.
17. Le Gal FA, Riteau B, Sedlik C, Khalil-Daher I, Menier C, Dausset J, Guillet JG, Carosella ED, Rouas-Freiss N: HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes. Int Immunol 1999; 11: 1351-1356. (Pubitemid 29355674)
18. Marchal-Bras-Goncalves R, Rouas-Freiss N, Connan F, Choppin J, Dausset J, Carosella ED, Kirszenbaum M, Guillet J: A soluble HLA-G protein that inhibits natural killer cell-mediated cytotoxicity. Transplant Proc 2001; 33: 2355-2359. (Pubitemid 33762740)
19. Gros F, Cabillic F, Toutirais O, Maux AL, Sebti Y, Amiot L: Soluble HLA-G molecules impair natural killer/dendritic cell crosstalk via inhibition of dendritic cells. Eur J Immunol 2008; 38: 742-749.
20. Agaugue S, Carosella ED, Rouas-Freiss N: Role of HLA-G in tumor escape through expansion of myeloid-derived suppressor cells and cytokinic balance in favor of Th2 versus Th1/Th17. Blood 2011; 117: 7021-7031.
21. Zidi I, Ben AN: HLA-G as predisposing for metastasis. Med Hypotheses 2011; 77: 134-139.
22. Yan WH: Human leukocyte antigen-G in cancer: are they clinically relevant? Cancer Lett 2011; 311: 123-130.
23. Bais AG, Beckmann I, Ewing PC, Eijkemans MJ, Meijer CJ, Snijders PJ, Helmerhorst TJ: Cytokine release in HR-HPV+ women without and with cervical dysplasia (CIN II and III) or carcinoma, compared with HR-HPV-controls. Mediators Inflamm 2007; 2007: 24147.
24. Clerici M, Merola M, Ferrario E, Trabattoni D, Villa ML, Stefanon B, Venzon DJ, Shearer GM, De Palo G, Clerici E: Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection. J Natl Cancer Inst 1997; 89: 245-250. (Pubitemid 27073762)
25. Kim J, Modlin RL, Moy RL, Dubinett SM, McHugh T, Nickoloff BJ, Uyemura K: IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T-cell immune response. J Immunol 1995; 155: 2240-2247.
26. Pazmany L, Mandelboim O, Vales-Gomez M, Davis DM, Becker TC, Reyburn HT, Seebach JD, Hill JA, Strominger JL: Human leucocyte antigen-G and its recognition by natural killer cells. J Reprod Immunol 1999; 43: 127-137. (Pubitemid 29349677)
27. Paul P, Rouas-Freiss N, Khalil-Daher I, Moreau P, Riteau B, Le Gal FA, Avril MF, Dausset J, Guillet JG, Carosella ED: HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci USA 1998; 95: 4510-4515. (Pubitemid 28207943)
28. Fukushima Y, Oshika Y, Nakamura M, Tokunaga T, Hatanaka H, Abe Y, Yamazaki H, Kijima H, Ueyama Y, Tamaoki N: Increased expression of human histocompatibility leukocyte antigen-G in colorectal cancer cells. Int J Mol Med 1998; 2: 349-351.
29. Riteau B, Menier C, Khalil-Daher I, Martinozzi S, Pla M, Dausset J, Carosella ED, Rouas-Freiss N: HLA-G1 co-expression boosts the HLA class I-mediated NK lysis inhibition. Int Immunol 2001; 13: 193-201. (Pubitemid 32123953)
30. Matsuda M, Salazar F, Petersson M, Masucci G, Hansson J, Pisa P, Zhang QJ, Masucci MG, Kiessling R: Interleukin-10 pretreatment protects target cells from tumor-and allospecific cytotoxic T cells and downregulates HLA class I expression. J Exp Med 1994; 180: 2371-2376.
31. Sharma S, Stolina M, Lin Y, Gardner B, Miller PW, Kronenberg M, Dubinett SM: T cellderived IL-10 promotes lung cancer growth by suppressing both T-cell and APC function. J Immunol 1999; 163: 5020-5028. (Pubitemid 29501270)
32. Urosevic M, Kurrer MO, Kamarashev J, Mueller B, Weder W, Burg G, Stahel RA, Dummer R, Trojan A: Human leukocyte antigen-G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. Am J Pathol 2001; 159: 817-824. (Pubitemid 32847172)
33. Yoon BS, Kim YT, Kim JW, Kim SH, Kim JH, Kim SW: Expression of human leukocyte antigen-G and its correlation with interleukin-expression in cervical carcinoma. Int J Gynaecol Obstet 2007; 98: 48-53. (Pubitemid 46898398)
34. Ramal LM, Feenstra M, van der Zwan AW, Collado A, Lopez-Nevot MA, Tilanus M, Garrido F: Criteria to define HLA haplotype loss in human solid tumors. Tissue Antigens 2000; 55: 443-448. (Pubitemid 30316155)
35. Rodríguez JA, Galeano L, Palacios DM, Serrano ML, Bravo MM, Combita AL: Frecuencias de las pérdidas de heterocigocidad en la región que codifica para HLA en biopsias de pacientes con cáncer de cuello uterino. Rev Colomb Cancerol 2009; 13: 191-204.
36. Feenstra M, Veltkamp M, van Kuik J, Wiertsema S, Slootweg P, van den TJ, de Weger R, Tilanus M: HLA class I expression and chromosomal deletions at 6p and 15q in head and neck squamous cell carcinomas. Tissue Antigens 1999; 54: 235-245. (Pubitemid 29443843)
37. Maleno I, Cabrera CM, Cabrera T, Paco L, Lopez-Nevot MA, Collado A, Ferron A, Garrido F: Distribution of HLA class I altered phenotypes in colorectal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Immunogenetics 2004; 56: 244-253. (Pubitemid 39119279)
38. Chen HX, Lin A, Shen CJ, Zhen R, Chen BG, Zhang X, Cao FL, Zhang JG, Yan WH: Upregulation of human leukocyte antigen-G expression and its clinical significance in ductal breast cancer. Hum Immunol 2010; 71: 892-898.
39. Kadish AS, Ho GY, Burk RD, Wang Y, Romney SL, Ledwidge R, Angeletti RH: Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia. J Natl Cancer Inst 1997; 89: 1285-1293. (Pubitemid 27371949)
40. Delgado FG, Martinez E, Cespedes MA, Bravo MM, Navas MC, Combita Rojas AL: Increase of human papillomavirus-16 E7-specific T-helper type 1 response in peripheral blood of cervical cancer patients after radiotherapy. Immunology 2009; 126: 523-534.
41. Urosevic M, Willers J, Mueller B, Kempf W, Burg G, Dummer R: HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent Bcell lymphomas. Blood 2002; 99: 609-617. (Pubitemid 34533099)
42. Aptsiauri N, Cabrera T, Mendez R, Garcia-Lora A, Ruiz-Cabello F, Garrido F: Role of altered expression of HLA class I molecules in cancer progression. Adv Exp Med Biol 2007; 601: 123-131.
43. Chang CC, Ferrone S: Immune selective pressure and HLA class I antigen defects in malignant lesions. Cancer Immunol Immunother 2007; 56: 227-236. (Pubitemid 44833096)
44. Boon T, van der Bruggen P: Human tumor antigens recognized by T lymphocytes. J Exp Med 1996; 183: 725-729. (Pubitemid 26113944)
45. Vermeulen CF, Jordanova ES, ter Haar NT, Kolkman-Uljee SM, de Miranda NF, Ferrone S, Peters AA, Fleuren GJ: Expression and genetic analysis of transporter associated with antigen processing in cervical carcinoma. Gynecol Oncol 2007; 105: 593-599. (Pubitemid 46734204)
46. Cabrera T, Lara E, Romero JM, Maleno I, Real LM, Ruiz-Cabello F, Valero P, Camacho FM, Garrido F: HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination. Cancer Immunol Immunother 2007; 56: 709-717. (Pubitemid 46348739)
47. Yang Y, Zhang J, Miao F, Wei J, Shen C, Shen Y, Xie W: Loss of heterozygosity at 6p21 underlying [corrected] HLA class I downregulation in Chinese primary esophageal squamous cell carcinomas. Tissue Antigens 2008; 72: 105-114. (Pubitemid 352009813)
48. de Gruijl TD, Bontkes HJ, van den Muysenberg AJ, van Oostveen JW, Stukart MJ, Verheijen RH, van der Vange N, Snijders PJ, Meijer CJ, Walboomers JM, Scheper RJ: Differences in cytokine mRNA profiles between premalignant and malignant lesions of the uterine cervix. Eur J Cancer 1999; 35: 490-497. (Pubitemid 29157871)
49. Sheu BC, Lin RH, Lien HC, Ho HN, Hsu SM, Huang SC: Predominant Th2/Tc2 polarity of tumor-infiltrating lymphocytes in human cervical cancer. J Immunol 2001; 167: 2972-2978.
50. Bermudez-Morales VH, Gutierrez LX, Cocer-Gonzalez JM, Burguete A, Madrid-Marina V: Correlation between IL-10 gene expression and HPV infection in cervical cancer: a mechanism for immune response escape. Cancer Invest 2008; 26: 1037-1043.
51. Ritz U, Momburg F, Pilch H, Huber C, Maeurer MJ, Seliger B: Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma. Int J Oncol 2001; 19: 1211-1220.
52. Sheu BC, Chiou SH, Chang WC, Chow SN, Lin HH, Chen RJ, Huang SC, Ho HN, Hsu SM: Integration of high-risk human papillomavirus DNA correlates with HLA genotype aberration and reduced HLA class I molecule expression in human cervical carcinoma. Clin Immunol 2005; 115: 295-301.
53. Li W, Deng XM, Wang CX, Zhang X, Zheng GX, Zhang J, Feng JB: Down-regulation of HLA class I antigen in human papillomavirus type 16 E7 expressing HaCaT cells: correlate with TAP-1 expression. Int J Gynecol Cancer 2010; 20: 227-232.
54. Moreau P, Drian-Cabestre F, Menier C, Guiard V, Gourand L, Dausset J, Carosella ED, Paul P: IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes. Int Immunol 1999; 11: 803-811. (Pubitemid 29237771)
55. Bukur J, Rebmann V, Grosse-Wilde H, Luboldt H, Ruebben H, Drexler I, Sutter G, Huber C, Seliger B: Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. Cancer Res 2003; 63: 4107-4111. (Pubitemid 36917934)
56. Zhou JH, Ye F, Chen HZ, Zhou CY, Lu WG, Xie X: Altered expression of cellular membrane molecules of HLA-DR, HLA-G and CD99 in cervical intraepithelial neoplasias and invasive squamous cell carcinoma. Life Sci 2006; 78: 2643-2649.
57. Goncalves MA, Le DM, Simoes RT, Rabreau M, Soares EG, Donadi EA, Carosella ED: Classical and non-classical HLA molecules and p16(INK4a) expression in precursors lesions and invasive cervical cancer. Eur J Obstet Gynecol Reprod Biol 2008; 141: 70-74.
58. Guimaraes MC, Soares CP, Donadi EA, Derchain SF, Andrade LA, Silva TG, Hassumi MK, Simoes RT, Miranda FA, Lira RC, Crispim J, Soares EG: Low expression of human histocompatibility soluble leukocyte antigen-G (HLA-G5) in invasive cervical cancer with and without metastasis, associated with papilloma virus (HPV). J Histochem Cytochem 2010; 58: 405-411.
59. Dong DD, Yang H, Li K, Xu G, Song LH, Fan XL, Jiang XL, Yie SM: Human leukocyte antigen-G expression in cervical lesions: association with cancer progression, HPV 16/18 infection, and host immune response. Reprod Sci 2010; 17: 718-723.
60. Moreau P, Flajollet S, Carosella ED: Nonclassical transcriptional regulation of HLAG: an update. J Cell Mol Med 2009; 13: 2973-2989.
61. Urosevic M, Dummer R: HLA-G and IL-10 expression in human cancer-different stories with the same message. Semin Cancer Biol 2003; 13: 337-342. (Pubitemid 38160932)
62. Mocellin S, Wang E, Marincola FM: Cytokines and immune response in the tumor microenvironment. J Immunother 2001; 24: 392-407. (Pubitemid 33029909)
63. Barrier BF, Kendall BS, Sharpe-Timms KL, Kost ER: Characterization of human leukocyte antigen-G expression in endometrial adenocarcinoma. Gynecol Oncol 2006; 103: 25-30. (Pubitemid 44389864)
64. Wang Y, Ye Z, Meng XQ, Zheng SS: Expression of HLA-G in patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2011; 10: 158-163.
65. Ye SR, Yang H, Li K, Dong DD, Lin XM, Yie SM: Human leukocyte antigen-G expression: as a significant prognostic indicator for patients with colorectal cancer. Mod Pathol 2007; 20: 375-383. (Pubitemid 46348337)
66. Yie SM, Yang H, Ye SR, Li K, Dong DD, Lin XM: Expression of human leukocyte antigen-G (HLA-G) correlates with poor prognosis in gastric carcinoma. Ann Surg Oncol 2007; 14: 2721-2729. (Pubitemid 47460633)
67. Ishigami S, Natsugoe S, Miyazono F, Nakajo A, Tokuda K, Matsumoto M, Okumura H, Douchi T, Hokita S, Aikou T: HLA-G expression in gastric cancer. Anticancer Res 2006; 26: 2467-2472. (Pubitemid 43980219)